San Diego's BioAtla has raised $30 million in equity from undisclosed Chinese investors, cash that will help push its pipeline of large-molecule treatments. The company is at work on what it calls conditionally active biologics, or CABs, which are immunotherapeutics that can be switched on in the presence of certain antigens, according to BioAtla. With the new cash, the company plans to accelerate its in-house pipeline of CAB products toward clinical development, all the while leaning on its new Chinese partners to help forge new relationships in that country. More